Doximity Leads Turnover Surge as AI Hopes Fuel 70% After-Hours Rally

Market Snapshot

Doximity Inc. (DOCS) experienced significant trading activity on August 6, 2026, recording a trading volume of $0.61 billion, which represented a substantial 960.5% increase from the previous day and ranked first among all stocks in terms of turnover for the session. Despite this surge in volume, the stock closed the regular trading session down 4.48%. This intraday decline occurred prior to the release of the company’s fiscal first-quarter 2027 financial results after market close, which subsequently triggered a sharp rally in after-hours trading. The dichotomy between the regular session decline and the after-hours surge highlights the market’s initial uncertainty giving way to strong bullish sentiment driven by updated forward-looking guidance, as investors reacted positively to the company’s ability to beat revenue expectations and raise its full-year outlook despite a minor miss on adjusted earnings per share.

Key Drivers

The primary catalyst for Doximity’s after-hours surge, which saw shares jump approximately 64% to 72% to reach levels around $35, was the company’s decision to raise its fiscal 2027 full-year revenue guidance. Management updated the revenue forecast to a range of $671 million to $681 million, an increase from the previous guidance of $664 million to $676 million. This new range sits slightly above the Wall Street consensus estimate of approximately $670.3 million. The upward revision signals management’s confidence in the company’s growth trajectory and suggests robust demand from key client segments, particularly in the pharmaceutical and hospital sectors. This guidance raise was the dominant factor influencing investor sentiment, effectively overshadowing other mixed financial metrics reported in the quarter.

Doximity’s fiscal Q1 2027 revenue performance was a key contributor to this positive market reaction. The company reported total revenues of $156.6 million, reflecting a 7% year-over-year increase from $145.9 million in the same period last year. This result beat the consensus analyst estimate of roughly $151.8 million by approximately $4.8 million. The beat demonstrates that Doximity’s core business model, which relies on digital services for U.S. medical professionals, continues to generate consistent top-line growth. The revenue strength was attributed to strong adoption of the platform’s clinical and commercial tools, indicating that the company is successfully monetizing its large user base of over 80% of U.S. physicians.

A significant secondary driver of the stock’s momentum was the rapid adoption of artificial intelligence products, specifically Doximity Ask and AI Search. CEO Jeff Tangney highlighted that Doximity Ask was the top-performing U.S.-based model in the NOHARM benchmark, a critical metric for clinical AI accuracy. Furthermore, the company reported that workflow active prescriber growth exceeded 30% year-over-year, while AI Search query growth accelerated by more than 25% quarter-over-quarter. This strong AI adoption is viewed by analysts as a key engine for future growth, with expectations that AI-driven products will further boost engagement and revenue in subsequent quarters, particularly in the second half of the fiscal year.

Despite the positive revenue and guidance news, the stock’s regular session performance was tempered by a slight miss on adjusted earnings per share. Doximity reported a non-GAAP EPS of $0.29, narrowly missing the consensus estimate of $0.30. Additionally, adjusted EBITDA for the quarter was $74.8 million, representing a margin of 48%, which was a decrease from the $79.8 million reported in the prior year period. Operating cash flow also declined by 32% year-over-year to $42 million, and free cash flow dropped by 34% to $39.6 million. However, the market’s reaction suggests that investors prioritized the higher revenue guidance and AI growth metrics over the short-term margin compression and minor EPS miss.

Looking ahead, Doximity provided specific guidance for the second quarter of fiscal 2027, projecting revenue between $170 million and $171 million. This estimate aligns closely with analyst expectations of approximately $171.95 million. For the full fiscal year, while revenue guidance was raised, the adjusted EBITDA guidance was set at $309 million to $329 million, which is below the consensus estimate of roughly $329 million. This divergence indicates that while top-line growth is expected to remain strong, management is anticipating some pressure on profitability margins in the near term, likely due to ongoing investments in AI infrastructure and product development. Nevertheless, the overall sentiment remains positive, with the raised revenue outlook providing a clear path for continued expansion in the digital health sector.